In the Obama administration’s final days, the National Cancer Institute is establishing an ambitious new program designed to allow scientists to more quickly access new drugs and compounds for novel research.
One of the last achievements of Vice President Joe Biden’s cancer moonshot initiative before he leaves office, the program was unveiled Wednesday and will begin as an agreement between the institute and six drug companies.